Dr. Stewart Low is the primary inventor of Novosteo's technology. He has worked on the development of fracture-targeted drugs for the past decade. He is holds seven patents related to Novosteo's core technology and has been instrumental in raising non-dilutive capital for Novosteo. 

Dr. Low has also spent time conducting research in the autoimmune division of Endocyte Inc. and in the device-testing group of Nelson Laboratories. In addition, he worked as a postdoctoral research associate in the chemistry department at Purdue University from 2015 until 2018.

Dr. Low received his BSc in Microbiology from Brigham Young University and his PhD in Bioengineering from the University of Utah.